First Half 2026 Recap - Pulmonology

H1 2026 was a defining period for pulmonology, bookended by a landmark COPD biologic program, a first-in-class antifibrotic context from late 2025 entering routine practice, and the most consequential IPF trial readout in years. The 2026 American Thoracic Society (ATS) International Conference served as the half-year's clinical centerpiece in May, while the American Academy of Allergy, Asthma & Immunology meeting in February and CHEST's first severe asthma biologic guideline in January set the tone for a field actively translating emerging evidence into prescribing frameworks.